Chinese Regulators Fast-Track Promising Two-Drug Combination for Blood Cancer Treatment

Beijing, Tuesday, 4 August 2026.
China fast-tracked InnoCare’s dual-drug therapy for blood cancer after clinical trials demonstrated a 100% response rate, significantly accelerating the approval process for this innovative treatment.